Volume 5.37 | Sep 24

Mesenchymal Cell News 5.37 September 24, 2013
Mesenchymal Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mesenchymal Cell News on Twitter
Adipose Mesenchymal Stromal Cells Isolated from Type 2 Diabetic Patients Display Reduced Fibrinolytic Activity
Scientists demonstrated that diabetic autologous adipose-derived MSCs (AdMSCs) cultured in the presence of blood sera expressed and released higher levels of plasminogen activator inhibitor type 1, reduced levels of tissue plasminogen activator and lower D-dimer formation as compared to non-diabetic AdMSCs. [Diabetes] Abstract
Watch the Video: Obtain Functional MSCs Xeno-Free with MesenCult-XF
PUBLICATIONS (Ranked by impact factor of the journal)
An Injectable Hydrogel Incorporating Mesenchymal Precursor Cells and Pentosan Polysulphate for Intervertebral Disc Regeneration
Researchers developed an injectable hydrogel system based on enzymatically-crosslinked polyethylene glycol and hyaluronic acid. They examined the effects of adding pentosan polysulphate, a synthetic glycosaminoglycan-like factor that has previously been shown to this gel system in order to induce chondrogenesis in mesenchymal precursor cells when added as a soluble factor, even in the absence of additional growth factors such as TGF-β. [Biomaterials] Abstract

Bioactive Membranes for Bone Regeneration Applications: Effect of Physical and Biomolecular Signals on Mesenchymal Stem Cell Behavior
Investigators focused on the in vitro characterization of bioactive elastin-like recombinamer membranes for bone regeneration applications. Four bioactive elastin-like recombinamers exhibiting epitopes designed to promote mesenchymal stem cell adhesion, endothelial cell adhesion, mineralization, and both cell adhesion and mineralization were synthesized using standard recombinant protein techniques [Acta Biomater] Abstract

LPS-Stimulated Inflammatory Environment Inhibits BMP-2-Induced Osteoblastic Differentiation through Crosstalk between TLR4/MyD88/NF-κB and BMP/Smad Signaling
Scientists showed that the inflammatory environment triggered by LPS in vitro would suppress bone morphogenetic protein-2 (BMP-2)-induced osteogenic differentiation of BMSCs, which was represented by decreased ALPase activity and down-regulated osteogenic genes. [Stem Cells Dev] Abstract

The Osteogenic Effect of Erythropoietin on Human Mesenchymal Stromal Cells Is Dose-Dependent and Involves Non-Hematopoietic Receptors and Multiple Intracellular Signaling Pathways
Scientists investigated the dose-response relationship and determined the lowest effective dose of erythropoietin that reliably increases the osteogenic differentiation of human mesenchymal stromal cells. [Stem Cells Rev] Abstract

Runx1 Is Critical for PTH-Induced Onset of Mesenchymal Progenitor Cell Chondrogenic Differentiation
Upon parathyroid hormone (PTH) treatment, limb bud mesenchymal progenitor cells in micromass culture showed an enhanced chondrogenesis, which was associated with a significant increase of chondrogenic marker gene expression, such as type II collagen and type X collagen. [PLoS One] Full Article

Monocyte Exosomes Stimulate the Osteogenic Gene Expression of Mesenchymal Stem Cells
Researchers showed that, under given experimental conditions, monocytes communicate with mesenchymal stem cells (MSCs) via exosomes, resulting in the uptake of exosomes in MSCs and the stimulation of osteogenic differentiation. [PLoS One] Full Article

Articular Cartilage-Derived Cells Hold a Strong Osteogenic Differentiation Potential in Comparison to Mesenchymal Stem Cells In Vitro
Researchers quantitatively assessed the mesenchymal differentiation potential of osteoarthritis patient cartilage-derived cells towards the osteogenic and adipogenic lineage in vitro and compared it to that of mesenchymal stem cells isolated from adipose tissue of healthy donors. [Exp Cell Res] Abstract

Sphingosine 1-Phosphate Receptors Negatively Regulate Expression of Collagen Type I/III Induced by Transforming Growth Factor-β1 in Human Bone Marrow-Derived Mesenchymal Stem Cell
Researchers provide evidence that sphingosine 1-phosphate receptor (S1PR)1/3, but not S1PR2, negatively regulates the expression of collagen in human bone marrow-derived mesenchymal stem cells using cellular and molecular approaches in vitro. [J Cell Biochem] Abstract

CD39-Mediated Effect of Human Bone Marrow-Derived Mesenchymal Stem Cells on the Human Th17 Cell Function
Human bone marrow-derived mesenchymal stem cells (hBMSCs) effectively suppressed the proliferation of Th17 cells and the secretion of both interleukin-17A and interferon-γ from Th17 cells using by both flow cytometry and ELISA, while anti-CD39 treatment significantly reduced the inhibitory effects of hBMSCs on the proliferation and secretion of the Th17 cells. [Purinergic Signal] Abstract

Hypoxia Enhances Chondrogenesis and Prevents Terminal Differentiation through PI3K/Akt/FoxO Dependent Anti-Apoptotic Effect
Mesenchymal stem cells (MSCs) induced for differentiation under hypoxia increased in chondrogenesis, but decreased in endochondral ossification compared to those under normoxia. MSCs induced for differentiation were more resistant to apoptosis under hypoxia compared to those under normoxia. [Sci Rep] Full Article

Achieve Superior Differentiation of Mouse MSC & MEF into Osteoblasts with the New MesenCult™ Osteogenic Stimulatory Kit (Mouse)
Human Mesenchymal Stem Cells and Their Paracrine Factors for the Treatment of Brain Tumors
The authors briefly summarize the biology of mesenchymal stem cells and discuss their properties and new development for brain cancer treatment. [Cancer Gene Ther] Abstract

Update on Therapeutic Mechanism for Bone Marrow Stromal Cells in Ischemic Stroke
The authors present an integrated consideration of molecular mechanisms in a chronological fashion and discuss an optimal bone marrow stromal cells delivery route for ischemic stroke. [J Mol Neurosci] Abstract

Visit our reviews page to see a complete list of reviews in the mesenchymal cell research field.

Attend World Stem Cell Summit 2013 in San Diego! Your Window to the World of Regenerative Medicine.
ACT Files Investigational New Animal Drug (INAD) Application with FDA to Treat 10 Different Disease Indications Using Pluripotent Stem Cells
Advanced Cell Technology, Inc. (ACT) announced that it has filed an INAD application with the Food and Drug Administration (FDA) to test its proprietary “off-the-shelf” mesenchymal stem cells in a range of different disease indications. [Advanced Cell Technology, Inc.] Press Release

STEMSOFT Announces Release of New Cord Banking Software Solution
STEMSOFT™ Software Inc. (“STEMSOFT”) announced the release of a new cord banking software solution, STEMSOFT CORD. This new system is like no other cord banking software on the market and offers an intuitive, easy to follow user interface paired with the functionality demanded by this unique workflow. [STEMSOFT Software, Inc.] Press Release

Harvard’s Wyss Institute and Charité, One of Europe’s Largest University Hospitals, Announce Partnership
The Wyss Institute for Biologically Inspired Engineering at Harvard University and Berlin-based Charité jointly announced a formal partnership. The announcement formalizes and elevates an existing collaboration between Wyss Core Faculty member David Mooney, Ph.D., and Georg Duda, Ph.D., Vice-Director of Charité’s Berlin-Brandenburg Center for Regenerative Therapies and Wyss Institute Associate Faculty member. [Hansjorg Wyss Institute for Biologically Inspired Engineering at Harvard University] Press Release

Enter Our Contest  
Mesenchymal Cell News is giving away a free registration for the World Stem Cell Summit 2013 in San Diego! Click here to enter “Your Window to the World of Regenerative Medicine”.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

From our sponsor:
Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
NEW TERMIS (Tissue Engineering and Regenerative Medicine International Society) America Conference
November 10-13, 2013
Atlanta, United States

Visit our events page to see a complete list of events in the mesenchymal cell community.
NEW 9 PhD Positions and 1 Postdoctoral Position – Tissue Engineering and Regenerative Medicine (RUNMC)

NEW Faculty Positions – Stem Cells and Regenerative Medicine (Baylor College of Medicine)

Postdoctoral Position – Cell Delivery Systems in Bone Repair (Fujifilm)

PhD Position – Biomaterial Imaging (Uppsala University)

Postdoctoral Position – Cardiopulmonary Molecular Biology (Hannover Medical School)

Principal Investigator – Developmental & Stem Cell Biology (SickKids Hospital)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Technologist – Mesenchymal Cell Research (STEMCELL Technologies Inc.)

Research Technologist – Cell Culture Media & Matrices (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)

Quality Control Analyst – Media (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Mesenchymal Cell News: Archives | Events | Contact Us